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Abstract
Cervical cancer is an important cause of mortality in women worldwide, and the cervix is a well-established clinical,
cytologic, and histopathologic model of carcinogenesis. The cervix is easily accessible for examination and biopsy,
and colposcopy improves visualization.
Identifying chemopreventives in cervical cancer requires rigorous study design: dose de-escalating phase I, IIa
trials; placebo-controlled phase IIb trials; and multicenter phase III trials. Reduction in disease incidence and
surrogate endpoint biomarkers (SEB) may be trial endpoints. The goal of chemoprevention studies is to prevent or
delay the development of cancer. Each agent requires a phase I or IIa trial for each organ site.
Phase I, IIa studies of micronutrients, retinoids, a-difluoromethylornithine, and indole-3-carbinol have
demonstrated response rates of up to 70%, but results of placebo-controlled phase IIb studies have been
disappointing and their findings confounded by the high regression rates in placebo-treated patients.
Enhancement of research methods, including sufficient enrollment guided by power calculations, uniform biopsy
at study entry and exit, and strict progression through trial design phases would ensure valid and reliable results.
Because human papillomavirus (HPV) is the major etiologic agent, pretrial laboratory and animal studies should
have demonstrated the efficacy of the chemopreventive agent to decrease HPV viral protein expression or HPV
tumor induction. SEB modulation must be characterized in any trial’s earliest phases before use in phases IIb and
III. Lessons learned in chemoprevention will serve as a basis for immunoprevention and vaccine trials.
Introduction
Cervical lesions have long been thought by pathologists
to be an instructive paradigm of progression from
mildly dysplastic lesions to severely dysplastic lesions
and potentially to invasive cancer. The accessibility of
the cervix allows clinicians to observe cervical lesions
over time using the magnifying lens of a colposcope;
these lesions show progressive vascular atypia as they
advance to neoplasia. This accessibility also allows the
cervix to be easily sampled for cells using the Papani-
colaou (Pap) smear and for tissue using colposcopically
directed biopsy. Just as the biopsy shows predictable
changes as lesions progress toward invasion, the Pap
smear affords a cytologic model of progression. These
factors make the cervix well suited for use in developing
screening, diagnostic, and preventive interventions. This
review will focus on the incidence and natural history of
cervical lesions, discuss study design issues related to
chemoprevention trials and phase II randomized clinical
trials, review phase II cervical chemoprevention trials,
and analyze why many of the trials’ findings may be
negative. The goal of chemoprevention is to prevent or
delay the development of cancer.
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Incidence of cervical lesions
According to the worldwide cancer incidence database
maintained by the World Health Organization, cervical
cancer is the third most common malignancy in women
worldwide, exceeded only by breast cancer and colorec-
tal cancer. Parkin et al. [1] estimated that approximately
371,200 cases of cervical cancer were diagnosed world-
wide in 1990, accounting for 10% of all cancers
diagnosed in women. When compared with the indus-
trialized countries of North America and western
Europe, many developing countries, where approxi-
mately 80% of all cases occur, are found to have higher
invasive cervical cancer incidence [1, 2]. The global
incidence and mortality rates also show wide geographic
variation, with a 21-fold difference between the highest
and lowest age-standardized rates worldwide. The high-
est incidences are reported in south-central Asia, south-
eastern Asia, South America, eastern Europe, and
eastern Africa.
In the United States, the Surveillance, Epidemiology,
and End Results (SEER) database tracks cervical cancer
and carcinoma in situ (CIS) incidence based on biopsy
results in a 10% population-based sample that is
representative of the country’s many ethnic groups.
According to this database, cervical cancer is the third
most common neoplasia of the female genital tract in
the United States, following cancers of the endometrium
and ovary. It was projected that, in 2002, 13,000 cases of
invasive cervical cancer and 65,000 cases of CIS would
be diagnosed in women in the United States and
approximately 4100 deaths would be attributed to
invasive cervical cancer [3, 4].
The precursors to invasive cervical cancer are called
squamous intraepithelial lesions (SIL) or cervical intra-
epithelial neoplasia (CIN). SIL are further classified as
high grade (HGSIL), which includes former CIN 2, 3,
and CIS, or low grade (LGSIL), which includes HPV-
infected tissue and CIN 1. Because SIL/CIN does not
have to be reported in the SEER database, its exact
incidence is unknown [5]. In the United States, the
prevalence of SIL can be estimated by comparing
prevalence in different clinical settings. Estimated SIL
prevalence ranges from 1.1% in women attending family
planning clinics to 13.7% in women attending sexually
transmitted disease clinics [5]. Additionally, the Nation-
al Breast and Cervical Cancer Early Detection Program
reported that more than 26,000 cases of SIL were
detected in 851,818 Pap smears from medically under-
served women, or a prevalence of 3.1% [6]. Kurman
et al. [7] estimated that 50 million Pap smears are
performed annually in the United States. Based on the
estimated range of 1.1–13.7% and the projection of 50
million annual Pap smears, the number of SIL cases in
the United States may vary from 550,000 to 6,850,000
cases per year.
Kurman et al. [7] estimated that, of the 50 million Pap
smears performed in the United States annually, 2.5
million showed LGSIL and cervical atypia. (Atypias are
not considered CIN or SIL.) However, the prevalence of
HGSIL in the United States can be estimated using two
large cohorts. In one cohort, which contained 8026
patients in a military setting who underwent screening as
part of their annual physical exam, 0.3% of the Pap
smears showed HGSIL [8]. In the other cohort, the
National Breast and Cervical Cancer Detection Pro-
gram, in which women are screened annually at health
department sites, HGSIL were evident in 1.1% of
100,500 Pap smears [9]. Again, using the percentages
of 0.3% and 1.1% and an estimated 50 million annual
Pap smears, HGSIL may be incident in 150,000 to
550,000 American women per year.
Thus cervical cancer and its precursors are an
important health problem and deserve innovative ther-
apies that are evaluated in rigorously designed clinical
trials. Chemoprevention is defined as the use of medi-
cations or micronutrients to prevent or delay the onset
of cancer. There have been many chemoprevention trials
in cervical cancer precursors; they are listed in Table 1
[10–31]. A summary of the problems encountered when
analyzing these studies is presented in Table 2.
Choosing an agent with preclinical activity
The epidemiologic evidence linking HPV measured by
polymerase chain reaction (PCR) to cervical cancer is
consistent across case series, case–control studies, and
cohort studies [32–36]. The International Agency for
Research on Cancer (IARC) coordinated an interna-
tional prevalence study of 1000 frozen biopsy specimens
from 22 countries and used assays based on PCR to
detect 25 HPV types. HPV was eventually detected in
99% of tumors. The most common HPV types were
HPV 16 in 49% of tumors, HPV 18 in 12%, HPV 45 in
8%, and HPV 31 in 5%. HPV 16 was the predominant
type in all countries except Indonesia. HPV 16 domi-
nated in squamous cell carcinomas and HPV 18 in
adenocarcinomas [36]. Muñoz and Bosch [34] summa-
rized the case–control and cohort studies using PCR for
detecting the presence and type of HPV. Five PCR-
based case–control studies reviewed by Muñoz, Bosch,
and colleagues demonstrated remarkably high adjusted
odds ratios for HGSIL, ranging from 15.5 to 122.3 for
the presence of any HPV type (15.5 [8.2–29.4], 42.0
[15.3–124.3], 20.8 [10.8–40.2], 72.8 [27.6–191.9], 56.9
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[24.8–130.6], 122.3 [38.5–388.9]) and ranging from 9.9 to
1279.9 for the presence of HPV 16 or 18 (295.5 [44.8–
1946.6], 180.0 [49.0–630.0], 9.9 [5.4–18.3], 182.4 [54.0–
616.1], 1279.9 [185.5–8829.8]) [33, 35]. For invasive
cancer, four PCR-based case–control studies were con-
sistent, demonstrating adjusted odds ratios ranging from
15.6 to 46.2 for the presence of any HPV (46.2 [18.5–
111.1], 15.6 [6.9–34.7], 37.1 [19.6–70.4], 32.9 [7.7–141.1])
and ranging from 5.5 to 74.9 for the presence of HPV 16
(14.9 [5.0–49.5], 5.5 [2.4–12.9], 74.9 [32.5–173.0]) [33,
35, 36]. Cohort studies from the United States, the
Netherlands, Spain, and Colombia show similar relative
risks of more than 15.5 (8.2–29.4) for the presence of
HPV detected using PCR-based methods (reviewed in
ref. 34). The molecular evidence for the role of HPV in
causing cervical cancer is equally compelling [37]. The
immune system also plays an important role in the
process, and several immunoprevention trials are under
way [38]. Since HPV is central, chemoprevention trials
should have a biologic rationale that includes decreased
expression of HPV.
Choosing a relevant precursor and sample size: the natural
history of SIL/CIN
The natural history of SIL/CIN was reviewed initially
by Patten in the 1950s, a report discussed and updated
recently by Ostor [39] and by Mitchell et al. [40]. Table 3
summarizes these reviews. Ostor clustered his review by
grade of CIN and described regression rates of 57% for
CIN 1, 43% for CIN 2, and 32% for CIN 3. He
indicated that overall only 1.7% of CIN 1–3 lesions
progressed to invasive cancer. Mitchell et al. clustered
studies by those followed by Pap only and compared
them to those followed by biopsy, separating entirely
those that had an entry diagnosis of CIS. CIN 1–3
lesions progressed to invasive cancer in 1–1.4% of cases,
Table 2. Problems with current cervical chemoprevention trials
Failure to choose an agent that decreases human papillomavirus (HPV) expression or decreases growth in HPV-positive cell lines or tissue
cultures
Failure to choose an agent that in preclinical work has shown promise in producing regression in precancerous lesions
Failure to choose a high-grade cervical intraepithelial neoplasia that is unlikely to regress without therapy (grade 2–3 or carcinoma in situ)
Failure to take natural history of the disease into account when calculating the sample size
Failure to perform a phase I trial to determine dose or range of doses prior to the phase II study
Failure to determine duration of dose prior to the phase II study
Failure to set a relevant desired treatment response rate and to design trial with the sample size necessary
Failure to design the trial with the desired difference in response rates between placebo and treated groups in mind
Failure to use colposcopically directed biopsy as an entry and exit test
Failure to define response – partial and complete – and to do so explicitly, quantitatively, and reproducibly
Table 3. Natural history of CIN in cohorts of untreated patients from two reviews














Studies clustered by CIN grade [39]
CIN 1 57.0 32.0 – 11.0 –
CIN 2 43.0 35.0 – 22.0 –
CIN 3 32.0 56.0 – 12.0 –
Overall all grades of CIN 1.7
Studies clustered by study design [40]
CIN 1–3 (no carcinoma in situ) followed
by Papanicolaou smear only
34.0 41.0 25.0 10.0 1.0
CIN 1–3 (no carcinoma in situ) followed
by Papanicolaou smear and biopsy
45.0 31.0 23.0 14.0 1.4
Carcinoma in situ followed by biopsy – – – – 36.0
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and if CIS lesions were present, the progression to
invasive cancer was much higher – 36%.
Ostor accepted the entry diagnosis as assigned by the
pathologist. Mitchell et al., in consideration of the
kappa value of 0.40 for both intra- and interobserver
agreement among pathologists in interpreting cervical
biopsy specimens, divided studies by design rather than
pathologic grade. Since CIS had higher intra- and
interobserver agreement among pathologists (>0.60),
this entity was listed in a separate category.
In each review, the studies included were cohorts of
patients followed prospectively with Pap or biopsy. The
studies that both authors reviewed ranged in duration
from six months to 25 years of follow-up. Some of the
studies included colposcopically directed biopsies, while
others included blinded biopsies. Very few of the studies
included HPV typing. While not all of the studies were
of the same caliber, both authors sought to be inclusive
rather than exclusive in their reviews. In conclusion,
cohorts of patients with LGSIL and HGSIL or CIN 1–3
followed by biopsy or Pap have reasonably high regre-
ssion rates ranging from 32% to 57%. CIS, followed
by biopsy only, has a higher rate of persistence and
progression.
How does treatment alter the natural history? Ran-
domized clinical trials of such treatments for SIL/CIN
as cryotherapy, laser therapy, and loop excision dem-
onstrate 2-year complete response rates of over 80%
regardless of the grade (reviewed in ref. 41). While
investigators may choose any level of anticipated benefit
in their studies, conventional therapy yields substantial
cure rates with minimal complications. Thus a reason-
able chemoprevention agent should probably have at
least a 40–50% anticipated benefit to provide an
advance in treatment to the patient over the natural
history and/or conventional therapy.
Based on the reviews by Oster and Mitchell et al.,
Table 4 shows the number of patients needed for study in
each patient group to demonstrate a statistically signif-
icant difference, determined by regression rate of the
disease based solely on the natural history. Given that
study subjects may experience a spontaneous regression,
the beneficial outcome of a randomized clinical trial may
be higher than predicted. In Table 5, we examine the
regression rates noted in the phase II clinical trials and
the sample sizes that would be required to obtain a preset
desired difference in the response rate of the treated
patients ranging from a 10% to 70% difference. Esti-
mates assume an alpha error of 5%, a two-sided
measure, and a power of 80%. In Table 6, we see what
the minimum detectable statistically significant differ-
ence would be for the phase II studies that are reported.
Only the sample sizes in the Meyskens et al. study [15]
and Bell et al. study [31] were sufficiently large to detect
the anticipated difference desired.
Chemoprevention trials design
Chemoprevention studies involve four elements. First,
high-risk cohorts must be identified. Second, suitable
medications with low toxicity and reasonable biologic
rationale must be selected. Third, the study design
should include, in order, phases I, IIa, IIb, and III.
Fourth, studies should include the use of surrogate
endpoint biomarkers (SEB). Rigorous trial design is
critical for the success of these studies [42, 43]. Good-
man [44] has outlined the relevant elements in the study
design of chemoprevention trials (Table 7). The biology
and use of biomarkers are woven into the design of
chemoprevention trials.
Phase I chemotherapy trials evaluate toxicity of a
drug at escalating doses. In contrast, phase I, IIa
chemoprevention trials are often dose de-escalating,
seeking the lowest dose at which biologic modulation of
the SEB occurs and tolerating little toxicity. The






Difference in response rate between treated group and placebo group
0.10 0.20 0.30 0.40 0.50 0.60 0.70
CIN 1; Ostor [39] 57 369 85 33 14 – – –
CIN 2; Ostor [39] 43 391 97 42 22 12 – –
CIN 3; Ostor [39] 32 365 95 43 24 14 9 –
CIN 1–3, observed using
Pap smear; Mitchell et al. [40]
34 372 96 43 23 14 8 –
CIN 1–3, observed using
biopsy; Mitchell et al. [40]
45 392 96 41 21 11 – –
Note: Estimates are based on data from natural history studies. Estimates assume a two-sided alpha error of 0.05 and a power of 0.80.
a Estimates of regression rates are from studies reported in Table 3.
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importance of establishing the correct dose for each
organ in these trials cannot be overemphasized. Levels
of the drug in various tissues of interest should be
studied as part of the phase I, IIa trial design. In
addition to establishing reasonable doses, the phase I,
IIa trials may also be used to identify which SEB are
modulated by the drug of interest. Phase II chemopre-
vention trials, like phase II chemotherapy trials, evalu-
ate the effectiveness of a drug in a given organ. Unlike
phase II chemotherapy trials, phase II chemoprevention
trials require a placebo group because of the spontane-
ous regression sometimes observed in preneoplastic
lesions. Phase IIa trials are short-term, include a placebo
group, look at responses, and may examine SEB
modulation. Phase IIb trials are longer, include a
concurrent blinded control group receiving a placebo,
and incorporate the use of SEB. Both phase III
chemotherapy trials and phase III chemoprevention
trials evaluate the cost–benefit ratio of treatments in
multicenter settings. However, in contrast to phase III
chemotherapy studies, which compare investigational
agents with standard therapies in groups of patients with
cancer, phase III chemoprevention studies evaluate
cancer incidence reduction in groups at high risk
for cancer. The use of SEB instead of the endpoint of
cancer incidence reduction allows these trials to have a
shorter duration and a lower cost and to use smaller
sample sizes [42, 43].
The importance of the phase I and IIa study designs in
chemoprevention cannot be overemphasized. Phase I
studies determine the minimally effective and biologi-
cally relevant dose of the chemopreventive agent in the
organ of interest and the relevant duration of therapy.
Phase I, IIa studies can be used not only to validate the
SEB but also to demonstrate the modulation of the SEB
by the study drug. Levels of the medication in the tissue
of interest should be studied as part of the phase I, IIa
study design because findings of phase I studies in one
organ site may not apply to another. In addition to
establishing reasonable doses, the phase I, IIa trials may
also be used to validate the SEB modulated by the
medication under study in the organ of interest, as SEB
modulated in one organ may not be modulated in
another organ by the same medication.
Phase II randomized clinical trial design issues
The Consolidated Standards of Reporting Trials (CON-
SORT) criteria have been designed to improve the
reporting of randomized clinical trials. The protocol
should prospectively define the hypothesis under study,
Table 5. Number of patients needed per group by regression rates and response rate differences between placebo and treatment groups
Chemopreventive, cervical disease, and study Regression rate
in placebo
group (%)a
Difference in response rate between treated group and placebo group
0.10 0.20 0.30 0.40 0.50 0.60 0.70
Retinoids
All-TRA/CIN 2; Meyskens et al. [15] 27 340 90 42 24 15 10 6
All-TRA/CIN 3; Meyskens et al. [15] 31 361 94 42 24 15 9 –
Micronutrients
b-Carotene/CIN 1–3; Romney et al. [19, 20] 50 388 93 38 19 – – –
b-Carotene/CIN 2–3; Berman [22] and
Keefe et al. [23]
32 361 95 43 24 14 9 –
b-Carotene/CIN 1–3; De Vet et al. [24] 41 389 97 42 22 13 – –
b-Carotene/atypia to CIN 2; Fairley et al. [25] 60 356 81 30 – – – –
b-Carotene/atypia to CIN 1; Mackerras et al. [26] 29 351 92 42 24 15 9 5
Folate/CIN 1–2; Butterworth et al. [27] 41 389 97 42 22 13 – –
Folate/CIN 1–2; Butterworth et al. [28] 66 322 69 23 – – – –
Folate/HPV to CIN 2; Childers et al. [29] 6 146 48 26 16 11 8 6
Adduct reducers
Indole-3-carbinol/CIN 2–3; Bell et al. [31] 0 70 28 17 12 9 7 5
Note: Estimates are based on data from phase II studies in the medical literature. Estimates assume an alpha error of 0.05, a two-sided measure,
and a power of 0.80.
a Regression rates are complete response rates or complete and partial response rates as reported by authors.
Negative cervical chemoprevention trials 861
describe the study population with inclusion and exclu-
sion criteria, describe the planned interventions and
their timing, describe the primary and secondary out-
come measures, state the anticipated sample size and
rationale for statistical analysis, define stopping rules,
and describe the randomization and blinding. In the
report of the results of a trial, the participant flow and
detailed analyses should be included [45].
The null hypothesis for cervical chemoprevention
trials is that the chemopreventive under study will
induce no difference in regression rates between treat-
ment and placebo arms. The alternate hypothesis is that
the regression rate will be higher in the treatment arm
than in the placebo by a given delta error or response.
SEB modulation may be a secondary hypothesis, which
asserts no change against the alternate hypothesis of an
increasing or decreasing measure, depending on the
marker.
The study population for chemoprevention trials is
drawn from colposcopy clinics where patients are re-
ferred for colposcopically directed biopsy after abnormal
Pap smear findings.While patients referred to colposcopy
clinics have Pap smear diagnoses ranging from atypias to
carcinomas, colposcopically directed biopsy is the stan-
dard used to establish diagnosis. Most trials exclude pati-
ents with findings suggestive of invasive cancer on Pap
smear, colposcopy, or colposcopically directed biopsy.
The ideal test at entry is the colposcopically directed
biopsy because it is the criterion standard. Using
cytology as an entry test incurs substantial false positives
and false negatives because the sensitivity and specificity
of the Pap smear are both approximately 60% [46]. A
meta-analysis indicated that the sensitivity of colposcop-
ically directed biopsy was 96%, while the specificity was
48% [47]. In a separate meta-analysis that examined
colposcopy as a screening tool, the sensitivity of colpos-
Table 6. Minimum delta necessary in completed phase II/III placebo-controlled cervical cancer chemoprevention trials to produce a statistically





Minimum delta between treated and placebo
groups for statistical significance (%)
Retinoids
All-TRA (topical), CIN 2;
Meyskens et al. [15]
All-TRA: 43%, placebo: 27%,
statistically significant
141 50
All-TRA (topical), CIN 3;
Meyskens et al. [15]




Folate, vitamin C, CIN 1–2;
Butterworth et al. [27]
10 mg folate: 14%, placebo:
41%, not statistically significant
47 80
Folate, CIN 1–2;
Butterworth et al. [28]
Folate: 64%, placebo: 66%, not
statistically significant
177 84
Folic acid, HPV/CIN 1–2;
Childers et al. [29]




De Vet et al. [24]
b-Carotene: 38%, placebo: 41% 137 65
b-Carotene, CIN 1–3;
Romney et al. [20]
b-Carotene: 46%, placebo: 50%,
not statistically significant
74 80
b-Carotene, atypia to CIN 2;
Fairley et al. [25]
b-Carotene: 63%, placebo: 60%,
not statistically significant
117 83
b-Carotene and vitamin C,
atypia to CIN 1;
Mackerras et al. [26]
b-Carotene: 46%, vitamin C: 26%,
b-Carotene + vitamin C: 23%,
placebo: 29%
141 52
b-Carotene, CIN 2–3; Berman
[22] and Keefe et al. [23]
b-Carotene: 32%, placebo: 32% 124 53
Adduct reducers
Indole-3-carbinol,
CIN 2–3; Bell et al. [31]
200 mg indole-3-carbinol: 50%, 400 mg
indole-3-carbinol: 44%, placebo: 0%
27 37
Note: Listed are completed phase II/III placebo-controlled cervical cancer chemoprevention trials with actual numbers of patients, rates of
regression, and minimum delta detectable with the current sample size (alpha error, 0.05; two-sided measure; power, 0.80).
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copy without biopsy was 86%, while the specificity was
83% [48]. Thus the Pap smear has a false-negative rate of
40% and a false-positive rate of 40%, allowing 40% of
patients to be misclassified. Colposcopy without biopsy
has a sensitivity and specificity of 85%, and the false-
negative and false-positive proportions are 15%, re-
sulting in about one-third the chance of misclassification
with Pap smear alone. Colposcopically directed biopsy
has a false-negative rate of 4%, while the false-positive
rate is 52%. This means that, with colposcopy, lesions
may be overcalled. Since histology should dictate study
entry, lesions that are falsely positive colposcopically
would be excluded. Thus the study entry and exit test
that would lead to the least misclassification would be
colposcopically directed biopsy since its sensitivity is
96% and the lack of specificity is not a problem if
histology is used as the criterion for entry.
The planned interventions during the study fall into
two categories: the dose and duration of the chemopre-
vention agent under study and the follow-up and
evaluation of re-sponse in the patients. The dose and
duration of the che-moprevention agent under study
should be determined by a phase I, IIa study in which
toxicity, dose, duration, tissue levels, and utility of SEB
are evaluated. The phase I, IIa trial should be performed
in the organ of interest. Using phase I data from trials in
another organ site may mislead the investigator. Simi-
larly, SEB vary among organ sites, and phase I, IIa trials
allow investigation of organ-appropriate markers. The
primary endpoint for a phase II randomized cervical
chemopre-vention trial should be a histopathologic
response. The secondary endpoint could be modulation
of one or more SEB.
While toxicity, response, or SEB modulation may
determine the best dose for the phase II study, the
duration is determined with greater difficulty. Once an
active dose is determined, a phase I study of duration
should be performed. Currently chemopreventives are
given for time periods ranging from 1 week to 1 year.
The goal with chemoprevention is to use the lowest and
best-tolerated dose with activity for the shortest period.
Therefore, careful studies of duration and biomarker
modulation are equally important as the phase I dose/
toxicity trial design.


























































No Yes Maybe Yes Yes Yes
Recruitment
evaluation
No No No Yes Yes Yes
Pharmacokinetics
evaluation
Maybe Yes No Yes Yes Yes
Efficacy evaluation No No Yes Yes Yes Yes













Accrual goal 20 25–100 25–100 100–1000 100–1000 >1000
Source: Adapted from Goodman [44].
a Not defined in Goodman [44] but used by many investigators.
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This study population is characterized by large losses
to follow-up. Many investigators are currently studying
barriers to participation in these trials. Patients have
reported problems – lack of transportation, lack of child
care, expense, and fear of developing cancer – as reasons
for nonparticipation. The trials of shortest duration and
lowest toxicity (those that lower these barriers and
maintain accrual) are those most likely to yield mean-
ingful results, though there may be a trade-off if
medications take longer than expected to be effective.
Since the colposcopically directed biopsy has the highest
sensitivity and specificity, it should be used to determine
response. The primary endpoint for a phase II random-
ized cervical chemoprevention trial should be a histo-
pathologic response; the secondary endpoint could be
modulation of a SEB.
Defining the response rate carefully is important in
any clinical trial. Given the variation in reading of
cervical biopsies, well-designed studies should include
consensus panel review of biopsies to ascertain response.
Quantitative pathology may resolve some of these
issues, but it is still not used in many trials. Investigators
have chosen many criteria for response. Prior to the
establishment of the Bethesda system, a partial response
was typically defined as a histologic regression of one
grade (e.g., CIN 3 to CIN 2). In some trials, investiga-
tors require a two-grade decrease (CIN 3 to CIN 1 or
HGSIL to LGSIL). There is no consensus yet on this
issue, and quantitative histomorphometry would help
considerably.
The secondary endpoint could be modulation of SEB.
The SEB of interest will vary according to the effects of
the medication under study. Because HPV is a central
cause of cervical cancer, the expression of viral load or
HPV oncoproteins may be universal markers for these
trials.
The anticipated sample size calculation should take
into account the natural history of the precursor lesion
being studied, the follow-up testing (biopsies during
study may induce regression), and the level of anticipated
response. The rationale for statistical analysis should be
clearly stated and take into account primary and
secondary endpoint analyses. Interim analyses generally
prove helpful in assessing the trial. Reviewing toxicity
and response in blinded fashion protects the patients.
Trials should be stopped if they are causing harm.
Review of completed and ongoing cervical cancer
chemoprevention trials
Cervical cancer chemoprevention trials to date are
summarized in Table 1. In all of these studies, patients
having CIN lesions were chosen as the high-risk cohort.
Promising cervical cancer chemopreventive agents that
have been or are being investigated include the retinoids,
retinyl acetate gel, all-trans-retinoic acid (all-TRA), and
N-(4-hydroxyphenyl)retinamide (4-HPR); micronutrients,
including b-carotene, folate, and vitamins; the polyamine
synthesis inhibitor, a-difluoromethylornithine (DFMO);
and the adduct reducer, indole-3-carbinol. These studies
have concentrated on histologic and/or cytologic and
colposcopic regression as endpoints. Until 1995, none of
the studies systematically used SEB or HPV typing.
Retinoid studies
The retinoids include vitamin A and its natural and
synthetic analogs. Natural vitamin A, its esters, and the
retinoic acid isomers all-TRA, 9-cis-retinoic acid, and
13-cis-retinoic acid currently are the most widely clini-
cally tested retinoids. These isomers are interconverted
in vivo and can activate a wide spectrum of retinoid
receptors, both retinoic acid receptors (RAR) and
retinoid X receptors. Current systemic therapy using
these agents is limited by substantial toxicity [49, 50].
Most cervical studies using these agents have involved
local application with a sponge.
One of the retinoid analogs that seems promising in
chemoprevention is 4-HPR. Most of the cellular and
molecular mechanisms by which retinoids act are
mediated by nuclear RAR; however, 4-HPR may act
by means of non-RAR mechanism. Support for this
contention has come from the study by Delia et al. [51],
who have shown that 4-HPR can induce apoptosis in
retinoic acid–resistant cells. Also, the substitution of an
N-substituted carboxyamide group for the terminal
carboxyl group is believed to account for the decreased
toxicity of 4-HPR compared with other retinoids,
making this drug a good choice for long-term use in
chemoprevention studies. Because of its different mech-
anism of action, 4-HPR has low systemic toxicity and
can be given orally.
In addition, retinoids have inhibitory effects on the
growth of HPV, making such compounds of particular
interest in cervical cancer chemoprevention. Specifically,
there are several mechanisms by which retinoic acid may
affect the HPV E6 and E7 transforming proteins.
Bartsch et al. [52] have demonstrated decreased expres-
sion of HPV messenger RNA in the presence of retinoic
acid. Retinoic acid has also been shown to increase the
secretion of transforming growth factor a (TGF-a) in
cells immortalized by HPV; TGF-a can suppress the
expression of the E6 and E7 proteins in cervical
epithelial cells [53–55]. Thus, the expression levels of
these factors may serve as markers of responsiveness.
864 M. Follen et al.
Romney et al. [10] reported on a phase I and II trial
using topical retinyl acetate gel in patients having CIN
1 and CIN 2. Patients treated themselves for 7 days
in three sequential menstrual cycles, applying the gel
intravaginally. Doses included the placebo and 3, 6, 9,
and 18 mg per 6 g of inert vehicle. No serious side
effects were noted, but approximately half of the
participants noted vulvar irritation and itching with
the 18-mg dose. Only 14% of the patients had vaginal
burning with any dose during the trial. The study also
showed that high compliance could be achieved, and it
determined an optimal dose of 9 mg for a phase II trial.
There is no published report of the phase II trial.
Phase I and II trials by Surwit et al. [11], Meyskens
et al. [12], and Weiner et al. [13] demonstrated that all-
TRA could be safely applied topically to the cervix using
a cervical sponge and cap. Patients having CIN 1, 2, and
3 received treatment from the investigators for 4 days,
using increasing dosages of topical all-TRA ranging
from 0.05% to 0.48%. Patients were seen for follow-up
at 1 week and 1 month after treatment. Roughly a third
of the patients experienced vaginal irritation, and
roughly half had vaginal burning. Only one patient
discontinued treatment because of these symptoms. A
regression rate of 45% was noted in patients who
received doses of 0.15–0.48% compared with 14% in
those who received lower doses. The optimal dose for a
phase III study was determined to be 0.37%.
One of us (F.M.) and his colleagues [15] have reported
the results of a randomized phase IIb trial of 0.372%
topical all-TRA in 141 patients having CIN 2 lesions
and 160 patients having CIN 3 lesions. Patients having
CIS were excluded from this study. Patients initially
received 0.375% all-TRA daily for 4 days and then for
2 days each at 3- and 6-month follow-up visits. Patients
also underwent a Pap smear and colposcopy at 9, 12, 15,
21, and 27 months; biopsies were performed at the 15-
month visit. Many of the patients were lost to follow-up.
Of 151 patients who received the placebo, 81 were
evaluated at 15 months and 25 were evaluated at
27 months. Also, of 150 patients who received all-
TRA topically, 88 were seen at 15 months, and 21 were
seen at 27 months. There was a statistically significant
rate of regression for patients with CIN 2 lesions but not
for those with CIN 3 lesions.
While no dose has yet been selected in the phase I trial
conducted by Ruffin et al. [56] using topical all-TRA,
an abstract reporting a study of biomarkers has been
published. In that study, 54 women were randomized to
one of three all-TRA dose levels. HPV was measured on
days 1 and 5 using PCR for HPV presence, semiquan-
titative PCR for viral load, and reverse transcriptase
PCR for E6 and E7 oncoprotein expression. Currently,
38% of white women and 4% of African-American
women in the study are HPV negative which, to some,
indicates HPV infection may not be a useful biomarker
in all patients [16] and, for others, raises questions about
the assay.
A phase II study of 4-HPR in chemoprevention of
cervical cancer was recently completed at The University
of Texas M. D. Anderson Cancer Center [17]. In
this study, 4-HPR was given orally to women with
biopsy-proven HGSIL; thus, its effects were systemic.
Patients underwent a complete medical history survey,
nutritional survey, sexual behavior interview, physical
examination, colposcopy, colposcopically directed
biopsies, HPV testing, blood count measurement, serum
chemistry analysis, nyctalopia testing, and smoking
cessation counseling. Plans called for patients to receive
4-HPR (200 mg/day with a 3-day drug holiday every
month) or placebo for 6 months. Patients were to be
monitored at 3-month intervals for 1 year using the
aforementioned tests. Crossover from placebo to 4-HPR
was to occur if progression was detected using cytology,
colposcopy, or biopsy. SEB to be studied in this trial
included quantitative cytology and histopathology (nu-
clear texture, size, and density) and biologic measures
of proliferation (proliferating cell nuclear antigen, or
PCNA), cellular regulation (epidermal growth factor
receptor, or EGFR, and RAR), differentiation (involu-
crin, cornifin), and genetic instability (chromosome
polysomy, aneuploidy). When an interim review indi-
cated at 12 months that one group had a significantly
poorer prognosis, researchers broke the code and found
that it was the treated group. Analysis showed complete
or partial responses in 25% of the treated group and
44% of the placebo group. Since a phase I study of 4-
HPR in the cervix had not been performed, all that can
be said is that 200 mg/day for 6 months is unfavorable
compared with placebo. A higher dose may have been
necessary in the cervix.
Micronutrient studies
Carotene and vitamin C
Romney et al. [18] conducted a randomized trial of
vitamin C in 28 women with CIN 1 or 2. Fourteen
women each received vitamin C (1 g/day) in split doses
or placebo. Compared with those in controls, serum
levels of vitamin C in patients receiving vitamin C were
significantly increased. No significant progression was
noted in the treatment arm. The investigators considered
this a pilot study and planned a larger phase I trial. No
true phase I study of vitamin C has been performed.
In a later study, Romney and colleagues [19] con-
ducted a phase II trial of b-carotene given at 30 mg/day
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in patients having CIN 2. They expected 138 patients to
be accrued. Results for 74 patients have been published,
showing no statistically significant difference in the
response of 39 patients who received b-carotene and 30
who received a placebo [20]. Additionally, two provoc-
ative cervical neoplasia biomarker reports have been
published. First, Ho et al. [57] reported the use of HPV
viral load in predicting persistent disease in an elegant
study that controlled for age, ethnicity, education,
duration of oral contraceptive use, age at first inter-
course, number of sexual partners, smoking status, and
HPV typing by Southern blot analysis and PCR. They
found that viral load was most predictive of persistent
disease; however, there was nomention of the effects of b-
carotene on viral load in this analysis. Second, Comerci
et al. [58] reported that tissue levels of TGF-a1 were
higher after b-carotene treatment than before treatment.
Tissue staining in this study was graded visually but not
measured quantitatively. No mention was made of how
many reviewers graded the tissue samples, but one of the
authors is a pathologist. Statistically significant increases
in TGF-a1 were seen across parabasal, midepithelial, and
superficial epithelia. Also, no histologic regression rate
was reported in this analysis.
Manetta et al. [21] undertook a phase I–II study of
oral b-carotene taken daily for 6 months by 30 patients
having CIN 1 or 2. The dose was not modulated in this
study. Five patients were removed from the study after
disease progression (two at 3 months, one at 6 months),
and three other patients were removed because of
pregnancy (one at 3 months, two at 6 months), leaving
27 evaluable patients at 6 months and 22 evaluable
patients at 12 months. Twenty-one (78%) of the 27
evaluable patients showed regression colposcopically at
6 months, while 10 (45%) of the 22 patients showed
regression colposcopically at 12 months.
In another trial, Berman [22] undertook a phase II
study of b-carotene in patients having CIN 2 or 3. They
expected to accrue 60 patients. Keefe et al. [23] reported
a 32% response rate in both b-carotene and placebo
arms of the trial. Additionally, Brewer et al. [59]
published a biomarker report of this series showing
the serial changes in colposcopic and cervicographic
findings in women enrolled in the trial. Data were
available for 23 subjects who had regression and 16 who
had persistent lesions. In this study, small lesions were
significantly more likely to regress than were larger ones.
Also, patients whose lesions had coarse punctation
(usually indicative of a higher grade) were significantly
more likely to have persistent disease. A centripetal
pattern of regression was also noted [59].
In yet another study, De Vet et al. [24] conducted a
randomized phase II clinical trial of b-carotene in 278
patients having CIN 1–3; patients received b-carotene
given at 10 mg/day for 3 months (n¼ 137) or placebo
(n¼ 141). They studied both the partial and complete
regression rates using colposcopically directed biopsy at
study entry and Pap smear or biopsy at study termina-
tion. The b-carotene group had a 39% response rate,
whereas the placebo group had a response rate of 41%.
In a later placebo-controlled phase II study, Fairley
et al. [25] administered b-carotene at 30 mg/day for
12 months to 117 patients having conditions ranging
from cervical atypia to CIN 2. The b-carotene group
had a 63% response rate compared with 60% in the
control arm. Finally, Mackerras et al. [26] conducted a
double-blind, placebo-controlled randomized study in
which 141 women having cervical atypia to CIN 1
received 30 mg of b-carotene only, 500 mg of vitamin C
only, both b-carotene and vitamin C, or neither for
2 years, using Pap smear or biopsy at the end of the
study for response. The response rates were as follows:
b-carotene only, 46%; vitamin C only, 26%; both, 23%;
and neither, 29%. There were no statistically significant
differences among these results. Thus all the b-carotene
studies are negative. Unfortunately, a true phase I dose-
finding study has not been done, so the optimal dose and
treatment duration are unknown.
Folate
Like b-carotene, folate, specifically red blood cell folate,
has been shown to be deficient in patients with CIN
compared with controls. These data have supported
folate supplementation as a chemopreventive strategy
for CIN [60]. Also, red blood cell folate levels below
660 nmol/L have been shown to enhance the suscepti-
bility of patients to HPV. Because folic acid acts as a
coenzyme in DNA synthesis for normal cellular growth,
proliferation, and differentiation, Pietrantoni et al. [55]
studied the regulation of HPV oncogene expression by
folic acid. Specifically, they studied c-fos, c-jun, and
HPV E6 expression in CaSki (HPV 16–positive) cell
lines treated with folic acid. They found diminished c-fos
and c-jun expression using Western blot analysis when
concentrations of folate greater than 100 nmol/L were
used. Similarly, E6 protein expression was diminished at
folate concentrations of greater than 100 nmol/L, sug-
gesting that the mechanism by which the transcription
regulators c-fos and c-jun were controlled involved
diminished viral E6 expression.
In addition, Butterworth et al. [27] published an
update of a phase II randomized trial in which patients
having CIN 1 and 2 lesions received folate (10 mg) or
vitamin C (10 mg) as a placebo for 90 days. An initial
report on 47 of the patients indicated that those receiving
folate were likely to experience cytologic regression of
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their lesions; however, in the final report on the 177
evaluable patients there were no statistically significant
differences in regression of lesions between those
who received folate and those who received vitamin C
[28]. A phase II multicenter study of folate supplemen-
tation performed by Childers et al. [29] had similarly
negative results. In this intergroup Southwest Oncology
Group study, 331 patients having koilocytotic atypia,
CIN 1, or CIN 2 were randomized to receive 5 mg
of folic acid or a placebo. There was no difference
between the groups in disease regression after treatment
for 3 months (p¼ 0.08) or 6 months (p¼ 0.23). Again,
no phase I dose-finding study has ever been carried out
for folate, so the optimal dose and duration are
unknown.
Polyamine synthesis inhibitors
DFMO is an irreversible inhibitor of ornithine decar-
boxylase (ODC), a key enzyme in the biosynthesis of
polyamines (putrescine, spermidine, and spermine) that
is now considered a putative proto-oncogene crucial for
the regulation of cell growth and transformation [61].
Blocking endogenous ODC prevents transformation of
rat fibroblasts by the temperature-sensitive v-src onco-
gene. The goals of using DFMO to block polyamine-
directed transformation are inhibition of transformation
under the influence of field cancerization and removal
of cells already transformed by apoptosis [62]. Tumor
formation in experimental animals is prevented by
inhibitors of ODC such as DFMO [63, 64].
A phase I study of DFMO was completed at M. D.
Anderson Cancer Center [30]. In this study, the medi-
cation was given orally as an elixir; thus, the effects were
systemic. DFMO was administered at five dose levels:
1.000, 0.500, 0.250, 0.125, and 0.060 g/m2. The patients
underwent a complete medical history survey; nutrition-
al survey; sexual behavior interview; physical examina-
tion; colposcopy; colposcopically directed biopsies;
HPV testing; blood counts; serum chemistry analysis;
audiogram; plasma DFMO measurement; ornithine
and arginine measurements; red blood cell polyamine
measurement; tissue DFMO, ODC, and polyamine
measurement; and smoking cessation counseling.
DFMO was administered for 1 month, and loop elec-
trosurgical excision of the cervix was performed at the
study conclusion. Thirty patients were enrolled in the
study and completed all studies, but only 29 were
evaluable because one patient took the wrong dose.
Favorable responses were seen at all dose levels. Overall
a 50% response rate was noted (complete and partial
responses). The polyamine biomarkers suggested that
0.50 g/m2 per day and 0.125 g/m2 per day would be of
interest for the phase IIb study, which is ongoing [30].
Quantitative histopathologic biomarkers showed statis-
tically significant decreases in DNA content in all
specimens at all dosages. Decreases in DNA content
were seen in both histologic responders and nonre-
sponders, though they were most significant in respond-
ers [65, 66]. Quantitative PCNA measurements showed
decreased proliferation of CIN 3 in all specimens at all
dose levels, with the most significant decreases noted in
histologic responders [67]. Additionally, MPM-2 was
measured in correlation with PCNA. Decreased rates of
mitosis correlated well with decreased rates of prolifer-
ation of the basal layer [68]. Finally, EGFR was
measured quantitatively and did not decrease signifi-
cantly with treatment; however, pretreatment levels of
EGFR were inversely correlated with DFMO response
[69]. An advance in the polyamine trial field would be
the development of immunohistochemical markers of
polyamine synthesis [70].
Adduct reducers
The principal medication in the adduct reducer category
currently being studied is indole-3-carbinol [31]. Indole-
3-carbinol occurs naturally in vegetables of the genus
Brassica, such as cabbage, broccoli, and brussels sprouts
[71, 72]. This promising anticancer agent induces G1 cell
cycle arrest in human breast cancer cell lines indepen-
dently of estrogen receptor status [73]. Indole-3-carbinol
can also reduce the incidence of spontaneous and
carcinogen-induced mammary tumors [73, 74]. Investi-
gators conducted a phase I study of indole-3-carbinol in
60 women at risk for breast cancer, with doses ranging
from 50 to 400 mg/day and using the urinary estrogen
metabolite ratio of 2-hydroxyestrone to 16-hydroxy-
estrone (2-OH/16-OH) as determined by enzyme-linked
immunosorbent assay as the SEB [75]. With regression
analysis, the researchers found that, from baseline, the
peak relative change of the ratio was significantly
greater in the group of women receiving high-dose
therapy (300 or 400 mg/day) than it was in the control
group or the group receiving low-dose therapy (50, 100,
or 200 mg/day). They concluded that the minimum
effective dose for indole-3-carbinol as a breast cancer
preventive was 300 mg/day and that at this dose, and
within their 4-week study period, the agent presented no
significant toxicity.
A phase I study of indole-3-carbinol in women with
CIN has not been performed. The biologic rationale for
the use of indole-3-carbinol in the cervix is that it has
been shown to prevent cervical cancer in HPV type 16
transgenic mice during 6 months of treatment [76].
Nineteen of 25 control mice developed cancer with
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estradiol administration, whereas only two of 24 mice
fed indole-3-carbinol developed cancer [76].
Bell et al. [31] have conducted a phase II study of
indole-3-carbinol at two dose levels in the cervix, using
doses from the phase I study in the breast. For 12 weeks
they treated 27 women having CIN 2 or CIN 3 with a
placebo (10 patients), 200 mg/day indole-3-carbinol
(eight patients), and 400 mg/day indole-3-carbinol (nine
patients). In their study indole-3-carbinol administra-
tion produced regression (4 of 8 [50%] at 200 mg/day
and 4 of 9 [44%] at 400 mg/day), while placebo
administration did not (0 of 10). The differences were
statistically significant.
Why phase II cervical chemoprevention trials have been
negative?
For all the phase II studies listed, the hypothesis under
study was regression of CIN. All the studies recruited
patients from the colposcopy clinic. Many studies looked
at high-grade lesions, but a few included patients with
low-grade lesions and atypias. The major issues in study
design in the existing trials are four: underpowering, lack
of phase I data for dose and duration of treatment, the
use of Pap or Pap and colposcopy for study entry, and
inconsistency in tests used at study entry and exit.
Underpowering
Part of the reason that chemoprevention of SIL/CIN
trials have not worked has to do with the natural history
of CIN and underpowering in studies. Using the esti-
mates derived from natural history and using the
regression rate seen in the placebo arm of these phase
II studies, sample sizes for CIN studies can be calculated.
If one desires a power of 0.80 and allows for an alpha
error of 0.05, the estimated sample size for a placebo-
controlled trial would be calculated assuming a level of
difference in two binomial proportions using the arc sine
transformation (ST Plan, Department of Biomathemat-
ics, M. D. Anderson Cancer Center, Houston, Texas).
The resulting estimates are listed in Tables 4 and 5. The
difference in response rate per arm varies from 0.10 to
0.70, meaning, for example, that if the response rate in
the placebo arm is 0.30 and there is a delta error, or
anticipated difference in response, of 0.20, the response
rate in the treatment arm is 0.50. A clinically relevant
delta error must be determined by the investigator. If a
difference of as little as 10% is expected between the
placebo and treated group, then having 350–400 subjects
per arm of study generally would be necessary. As the
expected differences in response rate increase, the num-
ber of subjects needed declines. Thus if a medication is
expected to have a high response rate, fewer subjects are
needed. The sample sizes and the regression rates in
Table 6 indicate that medications would have had to
produce at least a 30% response rate in order to produce
a statistically significant difference between the two
groups. When we calculate the minimum delta that
could have been detected given the regression rate and
the sample size, most studies, with the exception of the
study by Childers et al. [29], would have required that the
medication be able to induce a 50–80% regression over
placebo (Table 6). This effect would have required agents
with a high level of activity. This table confirms that only
the studies of Meyskens et al. [15] and Bell et al. [31]
were sufficiently powered to detect a difference.
In conclusion, with regard to sample size and power
calculations, the following variables must be taken into
account: the entry diagnosis (grade of CIN/SIL), how the
patients will be observed (biopsy or cytology), the
duration of follow-up, and the anticipated difference of
interest in response between the placebo and treatment
arms. Specifically, the lower the CIN grade, the larger the
number of patients required to demonstrate an enhanced
rate of regression, given the natural history of the disease.
Also, if the patients are to be observed using biopsy, more
patients must be studied because there is a slightly higher
rate of regression anticipated with biopsies.
Lack of phase I, IIa data
Phase I trials of retinyl acetate gel [10], all-TRA [11–13],
and DFMO [30] for cervical neoplasia have been
conducted prior to conducting the phase II studies
(Table 8). In contrast, there has never been a phase I
trial of vitamin C, folate, 4-HPR, or indole-3-carbinol
for cervical neoplasia. How were the doses chosen? The
doses for vitamin C and folate were known to be safe.
The doses for the 4-HPR and indole-3-carbinol trials
were taken from breast cancer studies. Lack of a phase I
trial may allow for a falsely negative phase II because a
biologically inactive dose or an insufficient duration may
be chosen.
None of the phase I studies conducted looked carefully
at duration of use. Duration needs to be adequately
studied. Once a biologically relevant dose is chosen,
other phase I trials should be performed to study dose
and duration of dose. These studies, done carefully,
would produce important biomarker modulation infor-
mation. Most of the published studies report losses to
follow-up, and experience would suggest that the short-
est duration possible will enroll and keep the greatest
numbers of patients; however, longer duration of use
may be necessary when patients have high-grade lesions.
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Adequate medication absorption was studied by
Romney et al. [18] and Meyskens et al. [11–13] but not
by other investigators. No studies have looked carefully
at tissue levels of medication. Some medications will
require an additional biopsy for assessment. The need
for additional biopsies suggests performing these tissue
level tests in phase I studies, in which response is not the
primary outcome, but rather tolerance and toxicity.
Study entry criteria, primary endpoint measures, and
misclassification
The entry and exit tests are summarized in Table 9. For
the test desired at entry, colposcopically directed biopsy
is the standard. The phase II studies of Butterworth
et al. [27, 28] used the Pap smear and colposcopy for
entry and exit. This could result in a 15% misclassifi-
cation of CIN lesions. Fairley et al. [25] used the Pap
smear alone for entry and exit, which might have
resulted in a 40% misclassification of severity of CIN.
Using two different tests – one at study entry and one at
study termination – permits differential misclassification
bias between points of entry and termination. Macker-
ras et al. [26], De Vet et al. [24], Butterworth et al. [27,
28], and Childers et al. [29] chose different tests for study
entry and study end. This may partially account for the
lack of drug effect noted in these studies.
Misclassification of Pap smears and cervical biopsy
specimens has been the subject of several thoughtful
reviews [39, 40, 61–67, 77, 78]. The interobserver and
intraobserver kappas for the review of Pap smears and
occult biopsies are in the 0.4–0.7 range of moderate
agreement. Triply blind reviews followed by a consensus
panel review are currently the accepted method for
obtaining a rigorous gold standard. Quantitative
pathology using Feulgen-based stoichiometric stains
may soon make quantitative what was previously
qualitative. DNA content, chromatin texture features,
and tissue architecture are offering algorithms that are
both quantitative and reproducible. The field is emerg-
ing but promising better mathematical separation
of diagnostic categories. Quantitative measure of bio-
markers can be correlated with qualitative pathology
to create classifications that may be more biologically
Table 8. Study designs used in cervical cancer chemoprevention trials by agent
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at risk than those seen qualitatively with the human
eye.
Defining the response rate carefully is important in
any clinical trial. Given the variation in reading of
cervical biopsies, well-designed studies should include
consensus panel review of biopsy specimens to ascertain
response. Another issue is that many investigators have
reported only partial response rates in their studies,
rather than complete responses, partial responses, and
total responses. Meyskens et al. [15] had well-defined
criteria for response and reported a complete response
rate. Investigators ideally should report both partial and
complete responses in tables, broken down by major
covariates such as diagnosis at entry. Meyskens et al.
[15], De Vet et al. [24], and Fairley et al. [25] reported
response rates by diagnosis; however, only De Vet and
colleagues reported both partial and complete responses
by diagnosis.
The future: how to conduct cervical cancer
chemoprevention studies
Future investigators of cervical cancer chemoprevention
need to follow the principles of good study design. Future
advances in cervical cancer chemoprevention trials de-
pend on the understanding of factors that have impeded
or limited the validity or generalizability of previous
interventions [79]. Principles applicable to the design of
randomized clinical trials include defining suitable co-
horts and carefully selecting the treatment modality in
relationship to the anticipated response, primary and
secondary outcome measures, and biologic rationale.
Suitable cohorts may have any grade of CIN, but the
sample size must account for the rate of regression
expected for that grade of CIN as determined by the
method of follow-up. The natural history of SIL/CIN is
characterized by regression rates of 32–57%, and sample
sizes should account for spontaneous regression rates
and the stipulated therapeutic objectives.
Chemoprevention trials should be well designed and
incorporate the use of biomarkers. Phase I, IIa studies in
patients with CIN that are carefully designed and include
a placebo group, SEB validation and variability deter-
mination, toxicity measures, and similar study entry and
termination testing are essential. Phase IIb placebo-
controlled studies and multicenter phase III studies
should build upon the knowledge obtained in the phase I,
IIa studies. The validation and determination of SEB
modulation are critical to the success of these studies.
The primary and secondary outcomes measure should
be clearly defined. Patients who are enrolled in the study
should have a diagnosis based on colposcopically
directed biopsy, which is the highest standard. Because
this test has the highest sensitivity, all participants
should undergo colposcopically directed biopsy at study
entry and termination. Response criteria need to be well
defined. Because of the large variation in reading of
Table 9. Study design for phase II studies
Study Test
At entry At termination
Retinoids
Meyskens et al. [15] Colposcopically directed biopsy Colposcopically directed biopsy
Micronutrients
Butterworth et al. [27] Pap smear and colposcopy Colposcopically directed biopsy
Butterworth et al. [28] Pap smear and colposcopy Colposcopically directed biopsy
Childers et al. [29] Colposcopically directed biopsy Pap smear and colposcopy
De Vet et al. [24] Colposcopically directed biopsy Pap smear or colposcopy or, if progression,
colposcopically directed biopsy
Romney et al. [19, 20] Colposcopically directed biopsy Colposcopically directed biopsy
Fairley et al. [25] Pap smear Pap smear
Mackerras et al. [26] Colposcopically directed biopsy Pap smear and colposcopy or, if progression,
colposcopically directed biopsy
Berman [22] and Keefe et al. [23] Colposcopically directed biopsy Colposcopically directed biopsy
Adduct reducers
Bell et al. [31] Colposcopically directed biopsy Colposcopically directed biopsy
870 M. Follen et al.
cervical biopsy specimens, consensus panels of patho-
logists blinded to study outcome should be used for
response evaluation. As quantitative and reproducible
measures of pathology emerge, they will add value in
assessing response quantitatively rather than qualita-
tively. In addition, authors should report as much raw
data as possible, including at least the entry diagnosis
and both partial and complete response rates.
There must be a biologic rationale for the choice of
medication, and the incorporation of appropriate SEB
will be based on the medication under study. SEB that
may be of interest in all studies include viral load and
HPV oncoprotein expression. Preclinical laboratory
work, including suppression of HPV oncoprotein expres-
sion in cell lines or prevention of HPV-induced tumors in
mice, would contribute to the biologic rationale.
Cervical cancer chemoprevention studies require of the
investigator depth of knowledge, familiarity with bio-
logic and epidemiologic principles, and persistence.
Much is now known about the natural history and
pathobiology of cervical cancer. This knowledge must be
used constructively to refine study designs in the future.
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